These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33842729)

  • 21. Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib.
    Ikesue H; Yamaoka K; Matsumoto A; Hirabatake M; Muroi N; Yamasaki T; Kawakita M; Hashida T
    Cancer Chemother Pharmacol; 2022 Jun; 89(6):833-838. PubMed ID: 35254504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
    Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
    Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Axitinib in sequential therapy in metastatic renal cell carcinoma.
    Kuchar A; Hryciuk B; Stec R; Mączewski M; Szczylik C
    Contemp Oncol (Pozn); 2016; 20(5):418-420. PubMed ID: 28373826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
    Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
    Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Axitinib as a third or further line of treatment in renal cancer: a single institution experience.
    Tsironis G; Liontos M; Kyriazoglou A; Koutsoukos K; Tsiara A; Kaparelou M; Zakopoulou R; Cohen A; Skafida E; Fontara S; Zagouri F; Bamias A; Dimopoulos MA
    BMC Urol; 2020 Jun; 20(1):60. PubMed ID: 32487200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axitinib: a review in advanced renal cell carcinoma.
    Keating GM
    Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationship between treatment-related hypertension and therapeutic efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell carcinoma].
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi Y; Zhou AP; Wang JW; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2016 Sep; 38(9):698-702. PubMed ID: 27647404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
    Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK
    Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor-targeted therapy.
    Calvo E; Grünwald V; Bellmunt J
    Eur J Cancer; 2014 May; 50(7):1321-9. PubMed ID: 24594299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.
    Nigro O; Pastore A; Tartaro T; Bolzacchini E; Tuzi A; Pinotti G
    Anticancer Drugs; 2019 Apr; 30(4):425-427. PubMed ID: 30640790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
    Rini BI; Escudier B; Hariharan S; Roberts WG; Tarazi J; Rosbrook B; Askerova Z; DeAnnuntis LL; Motzer RJ
    Clin Genitourin Cancer; 2015 Dec; 13(6):540-7.e1-7. PubMed ID: 26320662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine Kinase Inhibitor-Induced Hypertension.
    Agarwal M; Thareja N; Benjamin M; Akhondi A; Mitchell GD
    Curr Oncol Rep; 2018 Jun; 20(8):65. PubMed ID: 29931399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.